PepGen Announces Topline Results from Lowest Dose (5 mg/kg) MAD Cohort in the Ongoing Phase 2 FREEDOM2 Study Demonstrating Favorable Safety, Splicing and vHOT Data

Go back to PepGen Announces Topline Results from Lowest Dose (5 mg/kg) MAD Cohort in the Ongoing Phase 2 FREEDOM2 Study Demonstrating Favorable Safety, Splicing and vHOT Data
(NASDAQ: PEPG) Delayed: 1.83 --0 (-0%)
Previous Close $1.83    52 Week High
Open $1.83    52 Week Low
Day High $1.83    P/E N/A 
Day Low $1.83    EPS
Volume 1,312